Targinta,Xintelassubsidiary with a focus on oncology, has initiated collaboration with Memorial Sloan Kettering Cancer Center(MSK) Therapeutics Accelerator for clinical development of integrin α10β1-targeted antibodies against aggressive sarcoma. Within the agreement, Targinta is responsible for producing the antibodies TARG9and TARG10while MSK is leading upcoming phase I/IIa studies. Targinta's portion of the collaboration will be financed through a directed new share issue to new investors directly in Targinta. Integrin α10β1 is expressed in 30-50 percent of aggressive sarcoma types with poor prognosis.
|
Published October 7, 2025
Xintela's subsidiary initiates collaboration with Memorial Sloan Kettering
Text:
News Desk [email protected]
Notes
Johnson & Johnson acquires Halda Therapeutics for $3 billion
Magle Group submits application for EmboCept S
Quia Pharma is delisted from Nasdaq
Stenocare acquires CannGros
Lundbeck enters the fight for Avadel
Klaria's partner CNX starts production of migraine film
Sofinnova Partners raises EUR 650 million in new fund
NEWSLETTER
Today's news roundup
News roundup Monday, November 17
Upcoming events
MedTech Summit 2026
A new, much-needed MedTech forum in one of Europe's leading life science clusters. As the first event of its kind...
Recommended
Pila Pharma stands out in next-generation obesity pipeline
Novo Nordisk challenges Pfizer in billion-dollar battle for Metsera
New major investment will strengthen Europe's life science sector
The pharmaceutical sector is riding a USD 61,6 billion R&D wave
SwedenBIO wants to give growth power to the industry
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account